These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
Delaware
|
36-3922969
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
7720 N. Lehigh Avenue, Niles, Illinois
|
60714
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Item
|
|
Page
|
|
|
|
|
|
Part I
|
|
|
|
|
|
|
|
1.
|
|
|
|
|
Consolidated Statements of Operations for the Three and Nine Months Ended October 31, 2014 and 2013
|
|
|
|
Consolidated Statements of Comprehensive (Loss) Income for the Three and Nine Months Ended October 31, 2014 and 2013
|
2
|
|
|
||
|
|
Consolidated Statements of Stockholders' Equity as of October 31, 2014 and January 31, 2014
|
|
|
|
Consolidated Statements of Cash Flows for the Nine Months Ended October
31, 2014 and 2013
|
|
|
|
||
|
|
|
|
|
2.
|
||
|
|
|
|
|
4.
|
||
|
|
|
|
|
Part II
|
|
|
|
|
|
|
|
6.
|
||
|
|
|
|
|
|
Three Months Ended October 31,
|
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
|
2014
|
|
2013
|
|
||||
|
Net sales
|
|
$43,819
|
|
|
$57,967
|
|
|
|
$156,713
|
|
|
$173,460
|
|
|
Cost of sales
|
37,098
|
|
41,080
|
|
|
123,458
|
|
130,423
|
|
||||
|
Gross profit
|
6,721
|
|
16,887
|
|
|
33,255
|
|
43,037
|
|
||||
|
|
|
|
|
|
|
||||||||
|
Operating expenses
|
|
|
|
|
|
||||||||
|
General and administrative expenses
|
5,291
|
|
7,550
|
|
|
19,421
|
20,760
|
|
|||||
|
Selling expenses
|
2,666
|
|
2,550
|
|
|
7,566
|
8,184
|
|
|||||
|
Total operating expenses
|
7,957
|
|
10,100
|
|
|
26,987
|
|
28,944
|
|
||||
|
|
|
|
|
|
|
||||||||
|
(Loss) income from operations
|
(1,236
|
)
|
6,787
|
|
|
6,268
|
|
14,093
|
|
||||
|
|
|
|
|
|
|
||||||||
|
Income from joint venture
|
903
|
|
715
|
|
|
1,114
|
|
248
|
|
||||
|
|
|
|
|
|
|
||||||||
|
Interest expense, net
|
293
|
|
276
|
|
|
793
|
|
1,082
|
|
||||
|
(Loss) income from continuing operations before income taxes
|
(626
|
)
|
7,226
|
|
|
6,589
|
|
13,259
|
|
||||
|
|
|
|
|
|
|
||||||||
|
Income tax expense (benefit)
|
11
|
64
|
|
|
1,553
|
|
(99
|
)
|
|||||
|
|
|
|
|
|
|
||||||||
|
(Loss) income from continuing operations
|
(637
|
)
|
7,162
|
|
|
5,036
|
|
13,358
|
|
||||
|
|
|
|
|
|
|
||||||||
|
Income (loss) from discontinued operations, net of tax
|
265
|
226
|
|
|
(217
|
)
|
9,510
|
|
|||||
|
|
|
|
|
|
|
||||||||
|
Net (loss) income
|
|
($372
|
)
|
|
$7,388
|
|
|
|
$4,819
|
|
$22,868
|
||
|
|
|
|
|
|
|
||||||||
|
Weighted average common shares outstanding
|
|
|
|
|
|
||||||||
|
Basic
|
7,290
|
|
7,068
|
|
|
7,238
|
|
6,995
|
|
||||
|
Diluted
|
7,290
|
|
7,163
|
|
|
7,337
|
|
7,041
|
|
||||
|
|
|
|
|
|
|
||||||||
|
(Loss) earnings per share from continuing operations
|
|
|
|
|
|
||||||||
|
Basic
|
($0.09)
|
|
$1.01
|
|
|
$0.70
|
$1.91
|
||||||
|
Diluted
|
($0.09)
|
|
$1.00
|
|
|
$0.69
|
$1.90
|
||||||
|
Earnings (loss) per share from discontinued operations
|
|
|
|
|
|
||||||||
|
Basic
|
$0.04
|
|
$0.03
|
|
|
($0.03)
|
|
$1.36
|
|
||||
|
Diluted
|
$0.04
|
|
$0.03
|
|
|
($0.03)
|
$1.35
|
||||||
|
(Loss) earnings per share
|
|
|
|
|
|
||||||||
|
Basic
|
($0.05)
|
|
$1.05
|
|
|
|
$0.67
|
|
|
$3.27
|
|
||
|
Diluted
|
($0.05)
|
|
$1.03
|
|
|
$0.66
|
|
$3.25
|
|
||||
|
|
Three Months Ended October 31,
|
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
|
2014
|
|
2013
|
|
||||
|
Net (loss) income
|
|
($372
|
)
|
|
$7,388
|
|
|
|
$4,819
|
|
|
$22,868
|
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive (loss) income
|
|
|
|
|
|
||||||||
|
Foreign currency translation adjustments, net of tax
|
(484
|
)
|
(58
|
)
|
|
(654
|
)
|
(778
|
)
|
||||
|
Interest rate swap, net of tax
|
(8
|
)
|
(4
|
)
|
|
(30
|
)
|
155
|
|
||||
|
Other comprehensive loss
|
(492
|
)
|
(62
|
)
|
|
(684
|
)
|
(623
|
)
|
||||
|
|
|
|
|
|
|
||||||||
|
Comprehensive (loss) income
|
|
($864
|
)
|
|
$7,326
|
|
|
|
$4,135
|
|
|
$22,245
|
|
|
(In thousands except per share data)
|
October 31, 2014
|
|
January 31, 2014
|
|
||
|
ASSETS
|
Unaudited
|
|
|
|||
|
Current assets
|
|
|
||||
|
Cash and cash equivalents
|
|
$14,416
|
|
|
$13,395
|
|
|
Restricted cash
|
429
|
|
439
|
|
||
|
Trade accounts receivable, less allowance for doubtful accounts of $177 at October 31, 2014 and $194 at January 31, 2014
|
40,975
|
|
45,659
|
|
||
|
Inventories, net
|
30,957
|
|
33,547
|
|
||
|
Assets held for sale
|
—
|
|
1,223
|
|
||
|
Prepaid expenses and other current assets
|
4,833
|
|
5,353
|
|
||
|
Costs and estimated earnings in excess of billings on uncompleted contracts
|
2,535
|
|
1,476
|
|
||
|
Total current assets
|
94,145
|
|
101,092
|
|
||
|
Property, plant and equipment, net of accumulated depreciation
|
42,279
|
|
42,541
|
|
||
|
Long-term assets
|
|
|
||||
|
Deferred tax assets
|
1,279
|
|
1,667
|
|
||
|
Note receivable
|
4,442
|
|
4,659
|
|
||
|
Investment in joint venture
|
7,669
|
|
6,550
|
|
||
|
Cash surrender value on life insurance policies
|
3,263
|
|
3,110
|
|
||
|
Other assets
|
2,530
|
|
2,363
|
|
||
|
Assets held for sale long-term
|
—
|
|
914
|
|
||
|
Patents, net of accumulated amortization
|
396
|
|
373
|
|
||
|
Total long-term assets
|
19,579
|
|
19,636
|
|
||
|
Total assets
|
|
$156,003
|
|
|
$163,269
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
||||
|
Current liabilities
|
|
|
||||
|
Trade accounts payable
|
|
$11,425
|
|
|
$15,276
|
|
|
Accrued compensation and payroll taxes
|
5,471
|
|
5,254
|
|
||
|
Commissions and management incentives payable
|
5,646
|
|
9,235
|
|
||
|
Current maturities of long-term debt
|
4,539
|
|
8,274
|
|
||
|
Customers' deposits
|
7,788
|
|
7,372
|
|
||
|
Liabilities held for sale
|
—
|
|
527
|
|
||
|
Billings in excess of costs and estimated earnings on uncompleted contracts
|
683
|
|
2,222
|
|
||
|
Other accrued liabilities
|
2,122
|
|
1,840
|
|
||
|
Deferred tax liabilities
|
920
|
|
889
|
|
||
|
Income taxes payable
|
1,271
|
|
2,593
|
|
||
|
Total current liabilities
|
39,865
|
|
53,482
|
|
||
|
Long-term liabilities
|
|
|
||||
|
Long-term debt, less current maturities
|
26,102
|
|
23,469
|
|
||
|
Deferred compensation liabilities
|
6,718
|
|
6,509
|
|
||
|
Liabilities held for sale long-term
|
—
|
|
968
|
|
||
|
Other long-term liabilities
|
2,215
|
|
2,203
|
|
||
|
Total long-term liabilities
|
35,035
|
|
33,149
|
|
||
|
Stockholders' equity
|
|
|
||||
|
Common stock, $.01 par value, authorized 50,000 shares; 7,291 issued and outstanding at October 31, 2014 and 7,169 issued and outstanding at January 31, 2014
|
73
|
|
72
|
|
||
|
Additional paid-in capital
|
52,474
|
|
52,144
|
|
||
|
Retained earnings
|
30,401
|
|
25,582
|
|
||
|
Accumulated other comprehensive loss
|
(1,845
|
)
|
(1,160
|
)
|
||
|
Total stockholders' equity
|
81,103
|
|
76,638
|
|
||
|
Total liabilities and stockholders' equity
|
|
$156,003
|
|
|
$163,269
|
|
|
($ in thousands, except share data)
|
|
Additional Paid-in Capital
|
Retained Earnings
|
Accumulated Other Comprehensive Income (Loss)
|
Total Stockholders' Equity
|
||||||
|
Common Stock
|
|||||||||||
|
Total stockholders' equity at January 31, 2013
|
$69
|
$50,358
|
$4,553
|
($725)
|
$54,255
|
||||||
|
|
|
|
|
|
|
||||||
|
Net income
|
|
|
21,027
|
|
|
21,027
|
|
||||
|
Stock options exercised
|
3
|
|
1,585
|
|
|
|
1,588
|
|
|||
|
Stock-based compensation expense
|
|
196
|
|
|
|
196
|
|
||||
|
Shares issued
|
|
5
|
|
|
|
5
|
|
||||
|
Interest rate swap
|
|
|
|
151
|
|
151
|
|
||||
|
Pension liability adjustment
|
|
|
|
966
|
|
966
|
|
||||
|
Foreign currency translation adjustments
|
|
|
2
|
|
(1,269
|
)
|
(1,267
|
)
|
|||
|
Tax benefit on above items
|
|
|
|
(283
|
)
|
(283
|
)
|
||||
|
Total stockholders' equity at January 31, 2014
|
$72
|
$52,144
|
$25,582
|
($1,160)
|
$76,638
|
||||||
|
|
|
|
|
|
|
||||||
|
Net income
|
|
|
|
$4,819
|
|
|
4,819
|
|
|||
|
Stock options exercised
|
1
|
|
329
|
|
|
|
330
|
|
|||
|
Stock-based compensation benefit
|
|
(57
|
)
|
|
|
(57
|
)
|
||||
|
Shares issued
|
|
58
|
|
|
|
58
|
|
||||
|
Interest rate swap
|
|
|
|
(40
|
)
|
(40
|
)
|
||||
|
Foreign currency translation adjustments
|
|
|
|
(653
|
)
|
(653
|
)
|
||||
|
Tax benefit on above items
|
|
|
|
8
|
|
8
|
|
||||
|
Total stockholders' equity at October 31, 2014
|
$73
|
$52,474
|
$30,401
|
($1,845)
|
$81,103
|
||||||
|
Shares
|
2014
|
|
2013
|
|
|
|
Balances at beginning of year
|
7,168,537
|
|
6,924,084
|
|
|
|
Shares issued
|
122,039
|
|
244,453
|
|
|
|
Balances at October 31, 2014
|
7,290,576
|
|
7,168,537
|
|
|
|
(In thousands)
|
Nine Months Ended October 31,
|
|||||
|
|
2014
|
|
2013
|
|
||
|
Operating activities
|
|
|
||||
|
Net income
|
|
$4,819
|
|
|
$22,868
|
|
|
Adjustments to reconcile net income to net cash flows provided by (used in) operating activities
|
|
|
||||
|
Depreciation and amortization
|
4,299
|
|
4,465
|
|
||
|
Loss (gain) on disposal of discontinued operations
|
283
|
|
(10,111
|
)
|
||
|
Deferred tax expense
|
420
|
|
93
|
|
||
|
Stock-based compensation (benefit) expense
|
(57
|
)
|
95
|
|
||
|
Income from joint venture
|
(1,114
|
)
|
(248
|
)
|
||
|
Cash surrender value on life insurance policies
|
(153
|
)
|
(131
|
)
|
||
|
Loss on disposal of fixed assets
|
4
|
|
305
|
|
||
|
Provision on uncollectible accounts
|
(592
|
)
|
(114
|
)
|
||
|
Changes in operating assets and liabilities
|
|
|
||||
|
Accounts receivable
|
5,108
|
|
(24,049
|
)
|
||
|
Inventories
|
2,434
|
|
3,044
|
|
||
|
Costs and estimated earnings in excess of billings on uncompleted contracts
|
(2,598
|
)
|
1,227
|
|
||
|
Accounts payable
|
(4,494
|
)
|
(7,052
|
)
|
||
|
Accrued compensation and payroll taxes
|
(3,309
|
)
|
4,329
|
|
||
|
Customers' deposits
|
416
|
|
1,669
|
|
||
|
Income taxes receivable and payable
|
(1,311
|
)
|
2,220
|
|
||
|
Prepaid expenses and other current assets
|
805
|
|
(3,736
|
)
|
||
|
Other assets and liabilities
|
107
|
|
(6,204
|
)
|
||
|
Net cash provided by (used in) operating activities
|
5,067
|
|
(11,330
|
)
|
||
|
|
|
|
||||
|
Investing activities
|
|
|
||||
|
Net proceeds from sale of discontinued operations
|
—
|
|
16,378
|
|
||
|
Capital expenditures
|
(4,208
|
)
|
(1,817
|
)
|
||
|
Proceeds from sales of property and equipment
|
8
|
|
8
|
|
||
|
Net cash (used in) provided by investing activities
|
(4,200
|
)
|
14,569
|
|
||
|
|
|
|
||||
|
Financing activities
|
|
|
||||
|
Proceeds from debt
|
62,876
|
|
76,633
|
|
||
|
Payments of debt on revolving lines of credit
|
(61,053
|
)
|
(70,446
|
)
|
||
|
Payments of other debt
|
(2,059
|
)
|
(6,817
|
)
|
||
|
Increase (decrease) in drafts payable
|
722
|
|
(118
|
)
|
||
|
Payments on capitalized lease obligations
|
(573
|
)
|
(453
|
)
|
||
|
Stock options exercised and restricted shares issued
|
388
|
|
911
|
|
||
|
Net cash provided by (used in) financing activities
|
301
|
|
(290
|
)
|
||
|
|
|
|
||||
|
Effect of exchange rate changes on cash and cash equivalents
|
(147
|
)
|
538
|
|
||
|
Net increase in cash and cash equivalents
|
1,021
|
|
3,487
|
|
||
|
Cash and cash equivalents - beginning of period
|
13,395
|
|
7,035
|
|
||
|
Cash and cash equivalents - end of period
|
|
$14,416
|
|
|
$10,522
|
|
|
|
|
|
||||
|
Supplemental cash flow information
|
|
|
||||
|
Interest paid
|
|
$1,165
|
|
|
$1,694
|
|
|
Income taxes paid
|
2,503
|
|
396
|
|
||
|
Fixed assets acquired under capital leases
|
614
|
|
20
|
|
||
|
Funds held in escrow related to the sale of Thermal Care, Inc. assets
|
61
|
|
1,125
|
|
||
|
1.
|
Basis of presentation.
The interim consolidated financial statements of MFRI, Inc. and subsidiaries ("MFRI," "Company," or "Registrant") are unaudited, but include all adjustments which the Company's management considers necessary to present fairly the financial position and results of operations for the periods presented. These adjustments consist of normal recurring adjustments. Information and footnote disclosures have been omitted pursuant to Securities and Exchange Commission ("SEC") rules and regulations. The consolidated balance sheet as of
January 31, 2014
is derived from the audited consolidated balance sheet as of that date. The results of operations for any interim period are not necessarily indicative of future or annual results. Interim financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company's latest Annual Report on Form 10-K. The Company's fiscal year ends on January 31. Years and balances described as
2014
and
2013
are for the
nine months ended October 31,
2014
and
2013
, respectively.
|
|
2.
|
Business segment reporting.
The Company has
two
reportable segments:
Piping Systems which engineers, designs, manufactures and sells specialty piping, leak detection and location systems
, and
Filtration Products, which manufactures custom-designed industrial filtration products to remove particulates from air and other gas streams
.
|
|
|
Three Months Ended October 31,
|
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
|
2014
|
|
2013
|
|
||||
|
Net sales
|
|
|
|
|
|
||||||||
|
Piping Systems
|
|
$26,540
|
|
|
$42,289
|
|
|
|
$102,683
|
|
|
$121,825
|
|
|
Filtration Products
|
17,279
|
|
15,678
|
|
|
54,030
|
|
51,635
|
|
||||
|
Total
|
43,819
|
|
|
$57,967
|
|
|
|
$156,713
|
|
|
$173,460
|
|
|
|
Gross profit
|
|
|
|
|
|
||||||||
|
Piping Systems
|
|
$4,609
|
|
|
$14,726
|
|
|
|
$25,913
|
|
|
$35,760
|
|
|
Filtration Products
|
2,112
|
|
2,161
|
|
|
7,342
|
|
7,277
|
|
||||
|
Total
|
|
$6,721
|
|
|
$16,887
|
|
|
|
$33,255
|
|
|
$43,037
|
|
|
Income (loss) from operations
|
|
|
|
|
|
||||||||
|
Piping Systems
|
|
$1,096
|
|
|
$9,403
|
|
|
|
$12,896
|
|
|
$21,276
|
|
|
Filtration Products
|
(726
|
)
|
(486
|
)
|
|
(1,300
|
)
|
(468
|
)
|
||||
|
Corporate
|
(1,606
|
)
|
(2,130
|
)
|
|
(5,328
|
)
|
(6,715
|
)
|
||||
|
Total
|
|
($1,236
|
)
|
|
$6,787
|
|
|
|
$6,268
|
|
|
$14,093
|
|
|
3.
|
Discontinued operations.
On April 30, 2013, the Company sold most of the domestic assets of its industrial process cooling subsidiary Thermal Care, Inc. to a subsidiary of IPEG, Inc. for
$16.4 million
cash. On
June 26, 2013
, the Company sold substantially all of the assets of the HVAC business previously included in Corporate. In October 2013, the Company decided to sell its remaining industrial process cooling business in Denmark. This business was sold on
February 28, 2014
. From October 2013 until the date of sale, the business was operational and selling product. These businesses are reported as discontinued operations in the consolidated financial statements, and the notes to consolidated financial statements have been revised to conform to the current year reporting. The
$317 thousand
of tax expense for the
nine
months ended
October 31, 2014
relates to the reversal of deferred tax assets on the books of the Denmark subsidiary upon the sale of that subsidiary. Results of the discontinued operations for the three and
nine months ended October 31,
2014 and 2013
were as follows:
|
|
|
Three Months Ended October 31,
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
2014
|
|
2013
|
|
||||
|
Net sales
|
|
$—
|
|
|
$874
|
|
|
$176
|
|
|
$13,049
|
|
|
|
|
|
|
|
||||||||
|
Gain (loss) on disposal of discontinued operations
|
|
$295
|
|
|
($12
|
)
|
|
$283
|
|
|
$9,750
|
|
|
(Loss) income from discontinued operations
|
(5
|
)
|
(551
|
)
|
(183
|
)
|
1,627
|
|
||||
|
Income (loss) from discontinued operations before income taxes
|
290
|
|
(563
|
)
|
100
|
|
11,377
|
|
||||
|
Income tax expense (benefit)
|
25
|
|
(789
|
)
|
317
|
|
1,867
|
|
||||
|
Income (loss) from discontinued operations, net of tax
|
|
$265
|
|
|
$226
|
|
|
($217
|
)
|
|
$9,510
|
|
|
|
|
|
|
|
||||||||
|
4.
|
Income taxes.
Income tax expense (or benefit) for each year is allocated to continuing operations, discontinued operations, extraordinary items, other comprehensive income, and other charges or credits recorded directly to stockholders’ equity. This allocation is commonly referred to as an intra-period tax allocation, as outlined in ASC 740, Income Taxes ("ASC 740"). When considering intra-period tax allocations, a company also should consider the accounting for income taxes in interim periods. ASC 740-20-45-7 requires that the tax effect of pretax income from continuing operations be determined without regard to the tax effects of items not included in continuing operations. This is commonly referred to as the "incremental approach", where the tax provision is generally calculated for continuing operations without regard to other items.
|
|
5.
|
Other intangible assets with definite lives.
The Company owns several patents, including those covering features of its piping and electronic leak detection systems.
Patents are capitalized and amortized on a straight-line basis over a period not to exceed the legal lives of the patents.
The Company expenses costs incurred to renew or extend the term of intangible assets
. Gross patents were
$2.66 million
and
$2.60 million
as of
October 31, 2014
and
January 31, 2014
, respectively. Accumulated amortization was approximately
$2.27 million
and
$2.23 million
as of
October 31, 2014
and
January 31, 2014
, respectively. Future amortizations over the next five years ending January 31 will be
$13,550
in
2015
,
$51,000
in
2016
,
$47,200
in
2017
,
$44,150
in
2018
,
$35,200
in
2019
, and
$205,200
thereafter.
|
|
|
Three Months Ended October 31,
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
2014
|
|
2013
|
|
||||
|
Patent amortization expense
|
|
$13
|
|
|
$12
|
|
|
$38
|
|
|
$38
|
|
|
6.
|
Investment in joint venture.
In
October 2009
, the Company invested
$5.9 million
, which consisted of
$2 million
for a
49%
interest and
$3.9 million
for a note receivable, in a Canadian joint venture with The Bayou Companies, Inc., a subsidiary of Aegion Corporation. The joint venture operates in Camrose, Alberta, Canada, which provides the Company the opportunity to participate in the growing oil sands market.
|
|
|
Nine Months Ended October 31,
|
|||
|
|
2014
|
|
2013
|
|
|
Income from joint venture
|
1,114
|
|
248
|
|
|
|
October 31, 2014
|
|
January 31, 2014
|
|
|
Current assets
|
$14,451
|
$13,034
|
||
|
Noncurrent assets
|
16,085
|
|
17,093
|
|
|
Current liabilities
|
4,184
|
|
2,921
|
|
|
Noncurrent liabilities
|
11,923
|
|
14,837
|
|
|
Equity
|
14,429
|
|
12,369
|
|
|
|
Nine Months Ended October 31,
|
|||||
|
|
2014
|
|
2013
|
|
||
|
Revenue
|
|
$28,666
|
|
|
$19,913
|
|
|
Gross profit
|
5,426
|
|
3,157
|
|
||
|
Income from continuing operations
|
3,820
|
|
1,570
|
|
||
|
Net income
|
2,268
|
|
516
|
|
||
|
7.
|
Stock-based
compensation.
The Company has stock-based compensation awards that can be granted to eligible employees, officers or directors.
|
|
|
Three Months Ended October 31,
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
2014
|
|
2013
|
|
||||
|
Stock-based compensation expense (benefit)
|
|
$74
|
|
|
($2
|
)
|
|
($217
|
)
|
|
$55
|
|
|
Restricted stock based compensation expense
|
|
$16
|
|
|
$62
|
|
|
$123
|
|
|
$288
|
|
|
|
Nine Months Ended October 31,
|
|
|
Fair value assumptions
|
2014
|
2013
|
|
Expected volatility
|
40.88% - 59.39%
|
49.65% - 65.54%
|
|
Risk free interest rate
|
.74% - 1.77%
|
.74% - 2.82%
|
|
Dividend yield
|
none
|
none
|
|
Expected life
|
4.9 - 5.1 years
|
4.9 - 5.7 years
|
|
Option activity
|
Options
|
Weighted Average Exercise Price Per Share
|
Weighted Average Remaining Contractual Term in Years
|
Aggregate Intrinsic Value
|
|||||
|
Outstanding at January 31, 2014
|
776
|
|
|
$11.69
|
|
6.1
|
|
$3,859
|
|
|
Granted
|
97
|
|
12.41
|
|
|
|
|||
|
Exercised
|
(45
|
)
|
7.27
|
|
|
155
|
|
||
|
Expired or forfeited
|
(61
|
)
|
19.35
|
|
|
|
|||
|
Outstanding end of period
|
767
|
|
11.45
|
|
6.0
|
857
|
|
||
|
|
|
|
|
|
|||||
|
Exercisable end of period
|
520
|
|
|
$12.09
|
|
4.7
|
|
$676
|
|
|
Unvested option activity
|
Unvested Options Outstanding
|
Weighted Average Exercise Price Per Share
|
Aggregate Intrinsic Value
|
|||||
|
Outstanding at January 31, 2014
|
263
|
|
|
$8.31
|
|
|
$1,633
|
|
|
Granted
|
97
|
|
12.41
|
|
|
|||
|
Vested
|
(102
|
)
|
|
|
||||
|
Expired or forfeited
|
(11
|
)
|
8.36
|
|
|
|||
|
Outstanding end of period
|
247
|
|
|
$10.10
|
|
|
$180
|
|
|
Restricted stock activity
|
Shares Outstanding
|
Weighted Average Exercise Price Per Share
|
Aggregate Intrinsic Value
|
|||||
|
Outstanding at January 31, 2014
|
29
|
|
|
$14.52
|
|
|
$419
|
|
|
Granted
|
84
|
|
12.41
|
|
|
|||
|
Issued
|
(80
|
)
|
|
|
||||
|
Outstanding end of period
|
33
|
|
|
$9.12
|
|
|
$305
|
|
|
8.
|
Earnings per share.
|
|
|
Three Months Ended October 31,
|
Nine Months Ended October 31,
|
||||||
|
|
2014
|
|
2013
|
|
2014
|
|
2013
|
|
|
Basic weighted average common shares outstanding
|
7,290
|
|
7,068
|
|
7,238
|
|
6,995
|
|
|
Dilutive effect of equity incentive plans
|
—
|
|
95
|
|
99
|
|
46
|
|
|
Weighted average common shares outstanding assuming full dilution
|
7,290
|
|
7,163
|
|
7,337
|
|
7,041
|
|
|
|
|
|
|
|
||||
|
Stock options not included in the computation of diluted earnings per share of common stock because the option exercise prices exceeded the average market prices of the common shares
|
346
|
|
216
|
|
257
|
|
362
|
|
|
|
|
|
|
|
||||
|
Stock options with an exercise price below the average market price
|
421
|
|
665
|
|
510
|
|
519
|
|
|
9.
|
Interest expense, net.
|
|
|
Three Months Ended October 31,
|
Nine Months Ended October 31,
|
||||||||||
|
|
2014
|
|
2013
|
|
2014
|
|
2013
|
|
||||
|
Interest expense
|
|
$432
|
|
|
$409
|
|
|
$1,175
|
|
|
$1,504
|
|
|
Interest income
|
(139
|
)
|
(133
|
)
|
(382
|
)
|
(422
|
)
|
||||
|
Interest expense, net
|
|
$293
|
|
|
$276
|
|
|
$793
|
|
|
$1,082
|
|
|
10.
|
|
|
11.
|
Fair value of financial instruments.
At
October 31, 2014
, an interest rate swap agreement that relates to a mortgage note in Denmark was in effect with a notional value of
$1.3 million
that matures
December 2021
. The swap agreement, which reduces the exposure to market risks from changing interest rates, exchanges the variable rate to fixed interest rate payments of
2.47%
. The exchange traded swap is valued on a recurring basis using quoted market prices and was classified within Level 2 of the fair value hierarchy, which includes significant other observable inputs because the exchange is not deemed an active market. The derivative mark to market was
$0.1 million
as of
October 31, 2014
and
January 31, 2014
. This was included in other long-term liabilities on the consolidated balance sheets.
|
|
12.
|
Recent accounting pronouncements
.
In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new standard provides for a single comprehensive model and supersedes most current revenue recognition guidance, including industry specific guidance, and provides for enhanced disclosure requirements. The objective of the new guidance is to improve the consistency, comparability and usefulness to users of financial statements. ASU 2014-09 provides for two implementation methods (1) full retrospective application to each prior period or (2) modified retrospective application with the cumulative effect as of the date of adoption. The Company is in the process of evaluating the new pronouncement which is effective for annual reporting periods beginning after December 15, 2016, and early application is not permitted.
|
|
|
Three Months Ended October 31,
|
|
Nine Months Ended October 31,
|
||||||||||||||
|
($ in thousands)
|
2014
|
|
%
|
|
2013
|
|
%
|
|
% Decrease
|
|
2014
|
%
|
|
2013
|
%
|
|
% Decrease
|
|
Net sales
|
$26,540
|
|
$42,289
|
|
(37)%
|
|
$102,683
|
|
$121,825
|
|
(16)%
|
||||||
|
Gross profit
|
4,609
|
|
17
|
%
|
14,726
|
|
35
|
%
|
(69)%
|
|
25,913
|
25
|
%
|
35,760
|
29
|
%
|
(28)%
|
|
Income from operations
|
1,096
|
|
4
|
%
|
9,403
|
|
22
|
%
|
(88)%
|
|
12,896
|
13
|
%
|
21,276
|
17
|
%
|
(39)%
|
|
|
Three Months Ended October 31,
|
|
Nine Months Ended October 31,
|
||||||||||||||||
|
($ in thousands)
|
2014
|
|
%
|
|
2013
|
|
%
|
|
% Increase (Decrease)
|
|
2014
|
|
%
|
|
2013
|
|
%
|
|
% Increase (Decrease)
|
|
Net sales
|
$17,279
|
|
$15,678
|
|
10%
|
|
$54,030
|
|
$51,635
|
|
5%
|
||||||||
|
Gross profit
|
2,112
|
|
12
|
%
|
2,161
|
|
14
|
%
|
(2)%
|
|
7,342
|
13.6
|
%
|
7,277
|
14.1
|
%
|
1%
|
||
|
Income from operations
|
(726
|
)
|
(4
|
)%
|
(486
|
)
|
(3
|
)%
|
(49)%
|
|
(1,300
|
)
|
(2
|
)%
|
(468
|
)
|
(1
|
)%
|
(178)%
|
|
10
|
|
Credit and Security Agreement with BMO HARRIS BANK N.A. dated September 24, 2014
|
|
31
|
|
Rule 13a - 14(a)/15d - 14(a) Certifications
(1) Chief Executive Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(2) Chief Financial Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32
|
|
Section 1350 Certifications (Chief Executive Officer and Chief Financial Officer certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)
|
|
101.INS
|
|
XBRL Instance
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition
|
|
101.LAB
|
|
XBRL Taxonomy Extension Labels
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation
|
|
Date:
|
December 9, 2014
|
/s/ Bradley E. Mautner
|
|
|
|
Bradley E. Mautner
|
|
|
|
Director, President and
|
|
|
|
Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
Date:
|
December 9, 2014
|
/s/ Karl J. Schmidt
|
|
|
|
Karl J. Schmidt
|
|
|
|
Vice President and Chief Financial Officer
|
|
|
|
(Principal Financial and Accounting Officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|